These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
229 related articles for article (PubMed ID: 30523709)
41. Effect of the 2013 ASCO-CAP HER2 Testing Guideline on the Management of IHC/HER2 2+ Invasive Breast Cancer. Yamada M; Kubo M; Yamamoto H; Yamashita N; Kai M; Zaguirre K; Kaneshiro K; Shimazaki A; Hayashi S; Kawaji H; Mori M; Oda Y; Nakamura M Anticancer Res; 2021 Aug; 41(8):4143-4149. PubMed ID: 34281885 [TBL] [Abstract][Full Text] [Related]
42. Management of Cancer-Associated Anemia With Erythropoiesis-Stimulating Agents: ASCO/ASH Clinical Practice Guideline Update. Bohlius J; Bohlke K; Castelli R; Djulbegovic B; Lustberg MB; Martino M; Mountzios G; Peswani N; Porter L; Tanaka TN; Trifirò G; Yang H; Lazo-Langner A J Clin Oncol; 2019 May; 37(15):1336-1351. PubMed ID: 30969847 [TBL] [Abstract][Full Text] [Related]
43. Impact of the updated 2018 ASCO/CAP guidelines on HER2 FISH testing in invasive breast cancer: a retrospective study of HER2 fish results of 2233 cases. Liu ZH; Wang K; Lin DY; Xu J; Chen J; Long XY; Ge Y; Luo XL; Zhang KP; Liu YH; Xu FP Breast Cancer Res Treat; 2019 May; 175(1):51-57. PubMed ID: 30712197 [TBL] [Abstract][Full Text] [Related]
44. Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO and OH (CCO) Joint Guideline Update. Hanna NH; Robinson AG; Temin S; Baker S; Brahmer JR; Ellis PM; Gaspar LE; Haddad RY; Hesketh PJ; Jain D; Jaiyesimi I; Johnson DH; Leighl NB; Moffitt PR; Phillips T; Riely GJ; Rosell R; Schiller JH; Schneider BJ; Singh N; Spigel DR; Tashbar J; Masters G J Clin Oncol; 2021 Mar; 39(9):1040-1091. PubMed ID: 33591844 [TBL] [Abstract][Full Text] [Related]
45. Initial Diagnostic Workup of Acute Leukemia: ASCO Clinical Practice Guideline Endorsement Summary of the CAP and ASH Guideline. de Haas V; Ismaila N; Zhang L J Oncol Pract; 2019 Feb; 15(2):101-105. PubMed ID: 30521418 [No Abstract] [Full Text] [Related]
46. Follow-up care, surveillance protocol, and secondary prevention measures for survivors of colorectal cancer: American Society of Clinical Oncology clinical practice guideline endorsement. Meyerhardt JA; Mangu PB; Flynn PJ; Korde L; Loprinzi CL; Minsky BD; Petrelli NJ; Ryan K; Schrag DH; Wong SL; Benson AB; J Clin Oncol; 2013 Dec; 31(35):4465-70. PubMed ID: 24220554 [TBL] [Abstract][Full Text] [Related]
47. HER2 Testing for Breast Cancer in the Genomics Laboratory: A Sea Change for Fluorescence In Situ Hybridization. Geiersbach KB; Sill DR; Meyer RG; Yuhas JA; Sukov WR; Mounajjed T; Carter JM; Jenkins RB; Chen B Arch Pathol Lab Med; 2021 Jul; 145(7):883-886. PubMed ID: 33112955 [TBL] [Abstract][Full Text] [Related]
48. Clinical Practice Guideline: Sudden Hearing Loss (Update). Chandrasekhar SS; Tsai Do BS; Schwartz SR; Bontempo LJ; Faucett EA; Finestone SA; Hollingsworth DB; Kelley DM; Kmucha ST; Moonis G; Poling GL; Roberts JK; Stachler RJ; Zeitler DM; Corrigan MD; Nnacheta LC; Satterfield L Otolaryngol Head Neck Surg; 2019 Aug; 161(1_suppl):S1-S45. PubMed ID: 31369359 [TBL] [Abstract][Full Text] [Related]
49. Implications of the Updated 2013 American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations on Human Epidermal Growth Factor Receptor 2 Gene Testing Using Immunohistochemistry and Fluorescence In Situ Hybridization for Breast Cancer. Lim TH; Lim AS; Thike AA; Tien SL; Tan PH Arch Pathol Lab Med; 2016 Feb; 140(2):140-7. PubMed ID: 26910218 [TBL] [Abstract][Full Text] [Related]
50. Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision Making for Early-Stage, Operable Breast Cancer: American Society of Clinical Oncology Endorsement of Cancer Care Ontario Guideline Recommendations. Henry NL; Somerfield MR; Abramson VG; Allison KH; Anders CK; Chingos DT; Hurria A; Openshaw TH; Krop IE J Clin Oncol; 2016 Jul; 34(19):2303-11. PubMed ID: 27001586 [TBL] [Abstract][Full Text] [Related]
51. Recommendations From the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. Teede HJ; Tay CT; Laven JJE; Dokras A; Moran LJ; Piltonen TT; Costello MF; Boivin J; Redman LM; Boyle JA; Norman RJ; Mousa A; Joham AE J Clin Endocrinol Metab; 2023 Sep; 108(10):2447-2469. PubMed ID: 37580314 [TBL] [Abstract][Full Text] [Related]
52. Laboratory Workup of Lymphoma in Adults: Guideline From the American Society for Clinical Pathology and the College of American Pathologists. Kroft SH; Sever CE; Bagg A; Billman B; Diefenbach C; Dorfman DM; Finn WG; Gratzinger DA; Gregg PA; Leonard JP; Smith S; Souter L; Weiss RL; Ventura CB; Cheung MC Arch Pathol Lab Med; 2021 Mar; 145(3):269-290. PubMed ID: 33175094 [TBL] [Abstract][Full Text] [Related]
53. Sentinel Lymph Node Biopsy and Management of Regional Lymph Nodes in Melanoma: American Society of Clinical Oncology and Society of Surgical Oncology Clinical Practice Guideline Update. Wong SL; Faries MB; Kennedy EB; Agarwala SS; Akhurst TJ; Ariyan C; Balch CM; Berman BS; Cochran A; Delman KA; Gorman M; Kirkwood JM; Moncrieff MD; Zager JS; Lyman GH J Clin Oncol; 2018 Feb; 36(4):399-413. PubMed ID: 29232171 [TBL] [Abstract][Full Text] [Related]
54. Molecular Biomarkers in Localized Prostate Cancer: ASCO Guideline. Eggener SE; Rumble RB; Armstrong AJ; Morgan TM; Crispino T; Cornford P; van der Kwast T; Grignon DJ; Rai AJ; Agarwal N; Klein EA; Den RB; Beltran H J Clin Oncol; 2020 May; 38(13):1474-1494. PubMed ID: 31829902 [TBL] [Abstract][Full Text] [Related]
55. Evaluation of Testing of Acute Leukemia Samples: Survey Result From the College of American Pathologists. George TI; Tworek JA; Thomas NE; Fatheree LA; Souers RJ; Nakhleh RE; Arber DA Arch Pathol Lab Med; 2017 Aug; 141(8):1101-1106. PubMed ID: 28537804 [TBL] [Abstract][Full Text] [Related]
56. HER2 FISH classification of equivocal HER2 IHC breast cancers with use of the 2013 ASCO/CAP practice guideline. Fan YS; Casas CE; Peng J; Watkins M; Fan L; Chapman J; Ikpatt OF; Gomez C; Zhao W; Reis IM Breast Cancer Res Treat; 2016 Feb; 155(3):457-62. PubMed ID: 26895325 [TBL] [Abstract][Full Text] [Related]
57. The future of Cochrane Neonatal. Soll RF; Ovelman C; McGuire W Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834 [TBL] [Abstract][Full Text] [Related]
58. ASCO/CAP 2018 breast cancer HER2 testing guidelines: summary of pertinent recommendations for practice in Australia. Farshid G; Bilous M; Morey A; Fox S; Lakhani S; Loi S; Bell R; Spillane A Pathology; 2019 Jun; 51(4):345-348. PubMed ID: 31076089 [TBL] [Abstract][Full Text] [Related]
60. Analysis of molecular subtypes for the increased HER2 equivocal cases caused by application of the updated 2013 ASCO/CAP HER2 testing guidelines in breast cancer. Guo L; Yuan P; Zhang J; Ling Y; Li W; Zhao B; Ying J; Xuan L Breast Cancer Res Treat; 2017 Nov; 166(1):77-84. PubMed ID: 28712009 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]